Loading...
NPI 1174137368 · Houston, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rapid Dx Laboratory LLC is a clinical medical laboratory provider located in Houston, Texas. This profile covers 60 Medicare and 64 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rapid Dx Laboratory LLC |
| Address | 5252 Hollister St. |
| City | Houston |
| State | TX |
| ZIP | 77040 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 3, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.8M |
| Medicaid | $927.8K |
RAPID DX LABORATORY LLC’s Medicare billing is concentrated in nucleic acid amplified-probe infectious disease testing, with top Medicare codes dominated by molecular diagnostics such as 87798, 87481, and 87631. The presence of high-volume claims for respiratory and pathogen panels (87631), Candida testing (87481), and the catch-all amplified-probe code 87798 indicates a service mix that centers on high-throughput molecular infectious disease testing rather than traditional chemistry or anatomic pathology work.
Revenue concentration on Medicare is high: the provider’s top three Medicare codes account for 58.0% of its total Medicare revenue, and a single code, 87798, alone contributes $2M in revenue (42.0% of Medicare). This concentration signals dependency on a small set of molecular test categories for the majority of Medicare receipts.
On Medicaid the revenue mix is similarly focused: the top three Medicaid codes account for 56.6% of Medicaid revenue, led by U0003 at $242.7K (27.4%) and 87798 at $162.4K (18.3%). This shows the provider runs a comparable molecular-testing-focused footprint in the state Medicaid program, with high-volume COVID PCR (U0003) and generalized amplified-probe testing (87798) representing the majority of Medicaid receipts.
The payer mix is Medicare-weighted: total Medicare revenue of $4.8M materially exceeds total Medicaid revenue of $927.8K, so Medicare is the dominant revenue source on a lifetime basis. Analysts should treat this entity as a Medicare-scale molecular lab that also participates meaningfully in state Medicaid testing, rather than a Medicaid-first operator.
Competitive standing on Medicare is strong for specific molecular tests: 87798 ranks #30 of 1319 providers nationally (98th percentile; notably above typical national volume) and 87631 ranks #11 of 636 (98th percentile; notably above typical national volume), while 87481 sits at the 97th percentile but is described as typical. These ranks indicate the provider is a national high-volume participant for selected amplified-probe diagnostics, achieving notably above-typical volumes for multiple respiratory and pathogen detection codes.
At the state Medicaid level the provider is a visible but not dominant participant: U0003 ranks #51 of 337 in-state (85th percentile; typical, unremarkable volume) and 87798 ranks #27 of 243 (89th percentile; typical, unremarkable volume). Medicaid percentiles cluster lower than the provider’s top Medicare percentiles, implying stronger national competitiveness than statewide dominance for its highest-revenue services.
Several individual CPT/HCPCS codes indicate statistically extreme or elevated volume beyond the top revenue drivers: 87651 is flagged as an "extreme outlier" (99th percentile) and 87496 is also an "extreme outlier" (98th percentile), while multiple other molecular assays (e.g., 87635) are "notably above typical" national volume. This pattern suggests RAPID DX operates high-volume workflows across a broad panel of molecular infectious-disease assays, not only its top three revenue codes.
The practice’s NPI was enumerated on 2020-09-03 (~6 years ago), indicating a relatively recent market entry that has nonetheless reached high national percentiles for several molecular test codes. The combination of recent enumeration and elevated national rankings implies rapid scale-up of high-throughput molecular testing capacity over a short operational window.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
60 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 57,970 | $30 | $2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 13,410 | $30 | $456K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 2,110 | $140 | $295.7K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 4,500 | $30 | $153.1K |
| 87556 | The lab analyst performs a test for Mycobacterium tuberculosis using amplified nucleic acid probe technique. Mycobacteria tuberculosis are sometimes called acid fast bacteria because of the special… | 3,360 | $40 | $137.9K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 4,000 | $30 | $136K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 3,900 | $30 | $132.7K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 3,560 | $30 | $121.2K |
| 87496 | The lab analyst performs a test for cytomegalovirus, or CMV, using amplified nucleic acid probe technique. CMV may cause severe illness in newborns and immunocompromised patients. | 3,360 | $30 | $114.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 2,260 | $50 | $113.2K |
Showing 1–10 of 60
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 60 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
60 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 11 | 300 | 790 | $30 | $265.1K |
| 87631 | 6 | 90 | 50 | $140 | $90.1K |
| G0483 | 55 | 170 | 150 | $240 | $84.9K |
| 87481 | 8 | 270 | 150 | $30 | $68.8K |
| G0482 | 127 | 200 | 150 | $190 | $54K |
| 87498 | 6 | 30 | 120 | $30 | $45.9K |
| 87529 | 4 | 60 | 90 | $30 | $43.6K |
| 87541 | 6 | 40 | 140 | $30 | $40.8K |
| G0480 | 98 | 140 | 80 | $110 | $38.8K |
| 87486 | 6 | 60 | 90 | $30 | $32.7K |
Showing 1–10 of 60
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
64 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 5,160 | $50 | $242.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 7,730 | $20 | $162.4K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 730 | $130 | $96K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 5,140 | $20 | $82.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 3,010 | $10 | $39.2K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 3,270 | $10 | $36K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,970 | $10 | $24.8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 790 | $20 | $17.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,990 | $10 | $15.9K |
| 87496 | The lab analyst performs a test for cytomegalovirus, or CMV, using amplified nucleic acid probe technique. CMV may cause severe illness in newborns and immunocompromised patients. | 4,480 | $1 | $13.4K |
Showing 1–10 of 64
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
64 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 51 | 340 | 400 | $50 | $553.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 38 | 120 | 340 | $120 | $422K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 94 | 160 | 200 | $110 | $323.8K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 86 | 150 | 170 | $30 | $302.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 27 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 76 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 45 | 300 | 410 | $20 | $223.4K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 17 | 140 | 180 | $60 | $215.9K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 47 | 150 | 320 | $20 | $184K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 44 | 100 | 650 | $50 | $161.3K |
Showing 1–10 of 64
Other providers in the same ZIP code as Rapid Dx Laboratory LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Laboratory Corporation Of America | TX | Clinical Medical Laboratory | $27.2M | $103.8M |
| Genview Diagnosis Inc | TX | Clinical Medical Laboratory | $1.1M | $8.9M |
| Jason Baron | TX | Psychiatry Physician | $127.6K | $0 |
| Mirlene Appolon | TX | Family Nurse Practitioner | $117.2K | $6.4K |
| Babatunde Otinwa | TX | Emergency Medicine Physician | $116.3K | $0 |
| Nowice Trexler | TX | Diagnostic Radiology Physician | $83.8K | $0 |
| Adam Alli | TX | Vascular & Interventional Radiology Physician | $81.2K | $0 |
| Jaideep Barge | TX | Diagnostic Radiology Physician | $40.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.